Furthermore, in combination with the SHP2 agonist lovastatin and ATR inhibitors, PARP1 can activate the cGAS-STING pathway and play an antitumor role in colon cancer and PBRM1-deficient renal clear cell carcinoma (120, 121). This evidence concerns the gene STING1 and colonic neoplasm.